# TMaxTree

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tmaxtree

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Website: www.tmaxtree.com/
- Total disclosed funding: $14M
- Latest round: Series B (Sep 2, 2024)
- Investors on record: 3

## About

Based in Wuxi, China, and founded in 2014, Jiangsu TMaxTree Biotechnology Co., Ltd., trading under the name TMaxTree, develops biological breeding equipment and technology services. The company focuses on high throughput breeding and screening technologies and has cooperated with Tsinghua University, the Chinese Academy of Sciences, and Jiangnan University. Its products have obtained CE and UL certification. In March 2026, the firm closed a venture funding round from CASH Capital.

The company works with research institutes and industry enterprises to provide full-stack biological breeding hardware and technology systems. Its core products include ARTP mutagenesis breeding instruments, automated high-throughput microbial droplet culture instruments, automated high-throughput strain selection platforms, and automated analysis and detection robots for biological reaction processes. Additionally, the company provides biological breeding CRO technology services utilizing droplet microfluidic cell culture and sorting technologies.

The company generates revenue from B2B contracts by selling specialized experimental analysis instruments and automation equipment to research institutions and biotechnology enterprises, as well as by providing biological breeding CRO technology development and consulting services.

## Funding rounds

- Series B, Sep 2, 2024, $14M — Tianjin Venture Capital, SinoKing Capital, Wuxi Xinfa Group

## Investors

- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series B
- SinoKing Capital (https://capitalatlas.ai/funds/sinoking-capital) — Series B
- Wuxi Xinfa Group — Series B